



Figure S1 Estimated OS according to different doses of cytarabine consolidation therapy in patients with different cytogenetics. (A) Patients with t(8;21)-only karyotype; (B) patients with additional -Y karyotype; (C) patients with additional -X karyotype; (D) patients with additional del(9q) karyotype; (E) patients with complex karyotype. LDAC, low-dose cytarabine; IDAC, intermediate-dose Ara-C; HiDAC, high-dose cytarabine; OS, overall survival; -Y, loss of Y chromosome; -X, loss of X chromosome.